This is a preview of subscription content, access via your institution.
Appelt, K., Bacquet, R.J., Bartlett, C.A, Booth, C.L., Freer, S.T., Fuhry, M.A.M., Gehring, M.R., Hermann, S.M., Howland, E.F., Janson, C.A., Jones, T.R., Kan, C., Kathardekar, V., Lewis, K.K., Marzoni, G.P., Matthews, D.A., Mohr, C.W.M.E., Morse, C.A., Oatley, S.J., Ogden, R.O., Reddy, M.R., Reich, S.H., Schoettlin, W.S., Smith, W.W., Varney, M.D., Villafranca, J.E., Ward, R.W., Webber, S., Webber, S.E., Welsh, K.M. and White, J., Design of enzyme inhibitors using iterative protein crystallographic analysis, J. Med. Chem., 34 (1991) 1925–1934.
Montgomery, J.A., Niwas, S., Rose, J.D., Secrist, J.A., Sudhakar Babu, Y., Bugg, C.E., Erion, M.E., Guida, W.C. and Ealick, S.E., Structure based design of inhibitors of purine nucleoside phosphorylase. 1.9-(arylmethyl) derivatives of 9-deazaguanine, J. Med. Chem., 36 (1993) 55–69.
Beveridge, D.L. and DiCapua, F.M., Free energy via molecular simulation, Ann. Rev. Biophys. Biophys. Chem., 18 (1989) 431–492.
McCammon, J.A., Free energy from simulation, Current Opinion in Structural Biology, 1 (1991) 196–200.
Merz, K.M., and Kollman, P.A., Free energy pertubation simulation of the inhibition of thermolysin: prediction of the free energy of binding of a new inhibitor, J. Am. Chem. Soc., 111 (1989) 5649–5658.
Rami Reddy, M., Viswanadhan, V.N. and Weinstein, J.N., Relative free energy differences in the binding free energies of human immunodeficiency virus 1 protease inhibitors: A thermodynamic cycle perturbation approach, Proc. Natl. Acad. Sci. USA, 88 (1991) 10287–10291.
Ferguson, D.M., Radmer, R.J. and Kollman, P.A., Determination of the relative binding free energies of peptide inhibitors to the HIV-1 protease, J. Med. Chem., 34 (1991) 2654–2659.
Tropshaw, A.J. and Hermans, J., Application of free energy simulations to the binding of a transition state analogue inhibitor to HIV protease, Prot. Eng., 5 (1992) 29–33.
Rao, B.G., Tilton, R.F. and Singh, U.C., Free energy perturbation studies on inhibitor binding to HIV-1 protease, J. Am. Chem. Soc., 114 (1992) 4447–4452.
Rami Reddy, M., Varney, M.D., Kalish, V., Viswanadhan, V.N. and Appelt, K., Calculation of relative differences in the binding free energies of HIV-1 protease inhibitors: A thermodynamic cycle perturbation approach, J. Med. Chem., 114 (1994) 10117–10122.
Bohacek, R.S. and McMartin, C., Definition and display of steric, hydrophobic, and hydrogen-bonding properties of ligand binding sites in proteins using Lee and Richards accessible surface: Validation of a high-resolution graphical tool for drug design, J. Med. Chem., 35 (1992) 1671–1684.
Kurtz, I.D., Meng, E.C. and Shoichet, B.K., Structure-based molecular design, Acc. Chem. Res., 27 (1994) 117–123.
Goodford, P.J., A computational procedure for determining energetically favorable binding sites on biologically important macromolecules, J. Med. Chem., 28 (1985) 849–857.
Boehm, H.-J., The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure, J. Comput.-Aided Mol. Design, 8 (1994) 243–256.
Sansom, C.E., Wu, J. and Weber, I.T., Molecular mechanics analysis of inhibitor binding to HIV-1 protease, Protein Eng., 5 (1992) 659–667.
Montgomery, J.A., Erion, M.D., Niwas, S., Rose, J.D., Secrist, J.A., Babu, S.Y., Bugg, C.E., Guida, W.C. and Ealick, S.E., Structure-based design of inhibitors of purine nucleoside phosphorylase. 1.9-(arylmethyl) derivatives of 9-deazguanine, J. Med. Chem., 36 (1993) 55–69.
Erion, M.D., Montgomery, J.A., Niwas, S., Rose, J.D., Ananthan, S., Allen, M., Secrist, J.A., Babu, S.Y., Bugg, C.E., Guida, W.C. and Ealick, S.E., Structure-based design of inhibitors of purine nucleo-side phosphorylase. 3. 9-arylmenthyl derivatives of 9-deazaguanine substituted on the methylene-group, J. Med. Chem., 36 (1993) 3771–3783.
Secrist, J.A.I., Niwas, S., Rose, J.D., Babu, S.Y., Bugg, C.E., Erion, M.D., Guida, W.C., Ealick, S.E. and Montgomery, J.A., Structure-based design of inhibitors of purine nucleoside phosphorylase. 2. 9-alicyclic and 9-heteroalicyclic derivatives of 9-deazaguanine, J. Med. Chem., 36 (1993) 1847–1854.
Viswanadhan, V.N., Rami Redy, M, Wlodawer, A., Varney, M.D. and Weinstein, J.N., An approach to rapid estimation of relative binding affinities of enzyme inhibitors: application to peptidomimetic inhibitors of the human immunodeficiency virus type 1 protease, J. Med. Chem., 39 (1996) 705–712.
Singh, U.C., Weiner, P.K., Caldwell, J.K. and Kollman, P.A., AMBER 3.3, University of California, San Francisco, CA, U.S.A., 1986.
Cramer, R.D., Patterson, D.E. and Bunce, J.D., Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins, J. Am. Chem. Soc., 110 (1988) 5959–5967.
Viswanadhan, V.N., Ghose, A.K. and Weinstein, J.N., Mapping the binding site of the nucleoside transporter protein: A 3D-QSAR study, Biochim. Biophys. Acta, 1039 (1991) 356–366.
Debnath, A.K., Hansch, C., Kim, K.H. and Martin, Y.C., Mechanistic interpretation of the genotoxicity of nitrofurans (antibacterial agents) using quantitative structure-activity relationships and comparative molecular field analysis, J. Med. Chem., 36 (1993) 1007–1016.
Depriest, S.A., Mayer, D., Naylor, C.B. and Marshall, G.R., 3D QSAR of angiotensin-converting enzyme and thermolysin inhibitors: A comparison of CoMFA models based on deduced and experimentally determined active site geometries, J. Am. Chem. Soc., 115 (1993) 5372–5384.
Kubinyi, H., 3D QSAR in drug design: Theory, methods and applications, ESCOM Science publishers B.V., Leiden, 1993.
Martin, Y.C., A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists, J. Comput.-Aided Mol. Design, 7 (1993) 83–102.
Waller, C., Oprea, T.I., Giolitti, A. and Marshall, G.R., Three-dimensional QSAR of human immunodeficiency virus (I) protease inhibitors: 1. A study employing experimentally-determined alignment rules, J. Med. Chem., 36 (1993) 4152–4160.
Oprea, T.I., Waller, C.L. and Marshall, G.R., 3D-QSAR of human immunodeficiency virus (I) protease inhibitors III: Interpretation of CoMFA results, Drug Design and Discovery, 12 (1994) 29–51.
Holloway, K., Wai, J.M., Halgren, T.A., Fitzgerald, P.M., Vacca, J.P., Dorsey, B.D., Levin, R.B., Thompson, W.J., Chen, J.L., deSolms, J.S., Gaffin, N., Ghosh, A.K., Giuliani, E.A., Graham, S.L., Guare, J.P., Hungate, R.W., Lyle, T.A., Sanders, W.M., Tucker T.J., Wiggins, M., Wiscount, C.M., Woltersdorf, O.W., Young, S.D., Darke, P.L. and Zugay, J.A., A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site, J. Med. Chem., 38 (1995) 305–317.
Halgren, T.A., MM force field, J. Comput. Chem., 17 (1996) 490.
Head, R.D., Smythe, M.L., Oprea, T.I., Waller, C.L., Green, S.M. and Marshall, G.R., VALIDATE: A new method for the receptor-based prediction of binding affinities of novel ligands, J. Am. Chem. Soc., 118 (1996) 3959–3969.
Chirlian, L.E. and Francl, M.M., Atomic charges derived from electrostatic potentials: A detailed study, J. Comp. Chem., 8 (1987) 894–905.
Frisch, M.J., Head-Gordon, M., Schelegel, H.B., Raghavachari, K., Binkley, J.S., Gonzales, C., Defrees, D.J., Fox, D.J., Whiteside, R.J., Seeger, R., Melius, C.F., Baker, J., Martin, R., Kahn, L.R., Stewart, J.J., Fluder, E.M., Topiel, S. and Pople, J.A., GAUSSIAN 88; Gaussian; Pittsburgh, PA, U.S.A., 1988.
Berendsen, H.J.C., Grigera, J.R. and Straatsma, T.P., The Missing Term in Effective Pair Potentials, J. Phys. Chem., 91 (1987) 6269–6271.
Rami Reddy, M. and Berkowitz, M., Dielectric constant of SPC/E water, Chem. Phys. Lett., 155 (1989) 173–176.
Rami Reddy, M., Viswanadhan, V.N. and Erion, M.D., Rapid estimation of relative binding affinities of enzyme inhibitors: Application to inhibitors of Fructose-1,6-bisphosphatase, J. Med. Chem. (to be submitted).
About this article
Cite this article
Reddy, M.R., Viswanadhan, V.N. & Erion, M. Rapid estimation of relative binding affinities of enzyme inhibitors. Perspectives in Drug Discovery and Design 9, 85–98 (1998). https://doi.org/10.1023/A:1027203803887
- Binding Affinity
- Enzyme Inhibitor
- Relative Binding
- Rapid Estimation